Patheon Appoints Michel Lagarde President

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-06-07-2016, Volume 11, Issue 6

Lagarde will be based out of the company’s Boston office and will lead Patheon’s global corporate and cross-enterprise operations.

On May 31, 2016, Patheon announced that it has appointed Michel Lagarde president of the company. Lagarde will be based out of the company’s Boston office and will lead global corporate and cross-enterprise operations. He will report to the Patheon CEO, James Mullen. Mullen will continue to direct the company’s global growth strategy and oversee its business segments, sales and marketing, and quality functions.

Lagarde joins Patheon from JLL Partners, a middle market private equity firm. For the past eight years, he has been working with several of JLL’s portfolio companies, including Patheon, in the healthcare and pharma services sectors as managing director. He has served as a member of Patheon’s Board of Directors since 2011. As a result of his appointment, Lagarde has stepped down from his position on Patheon’s Board of Directors.

Advertisement

Source: Patheon